Generates Adjusted EBITDA of $3.6 million and EPS of $0.05 (CDN$0.61) Excluding legal provision EPS was $0.10 (CDN$0.12) OAKVILLE, ON, May 13, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH)...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced it will release its Q1 2021 financial results after market close on Thursday, May 13, 2021. The company will hold...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has received approval from the Toronto Stock Exchange ("TSX") to amend its normal course issuer bid...

Adjusted EBITDA increases 9% to $13.7 million and EPS increases 60% to $0.16 (CDN$0.211) for the full year OAKVILLE, ON, March 18, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q4 2020 financial results after the close on Thursday, March 18, 2021. The company will hold...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has entered into an exclusive co-promotion agreement (the "Agreement") with Verity Pharmaceuticals Inc. for...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has received an arbitration award in the previously announced dispute between the Company and Bausch Health...

Revenue Increases Sequentially to $4.9 million EBITDA2 was $2.7 million or 55% of net revenue OAKVILLE, ON, Nov. 12, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company")...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q3 2020 financial results after the close on Thursday, November 12, 2020. The Company will...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today the voting results for the election of directors at its Annual Meeting of Shareholders held earlier today. A...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, a Notice of Intention to Make a...

Income before taxes increased 36% to $2.5 million EBITDA increased 22% to $2.9 million Excluding a one-time tax adjustment EPS was $0.07 (CDN$0.10) OAKVILLE, ON, Aug. 12, 2020 /CNW/ - Cipher...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q2 2020 financial results after the close on Wednesday, August 12, 2020. The Company will...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") is pleased to announce that it has appointed seasoned Financial Executive Scott Langille as its new Chief Financial Officer...

Earnings per common share increases to $0.10 ($0.13 in Canadian Dollars1) OAKVILLE, ON, May 7, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced it will release its Q1 2020 financial results on Thursday, May 7, 2020. The company will hold a conference call on...

Adjusted EBITDA reaches $4.2 million and Net income increases to $2.6 million in the fourth quarter OAKVILLE, ON, March 25, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q4 2020 financial results conference call on Thursday, March 26, 2019. CONFERENCE CALL DETAILS...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") is pleased to announce that Sun Pharmaceutical Industries Ltd. ("Sun Pharma"), the Company's U.S. marketing partner for...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the Company received a Notice of Termination (the "Notice") from Bausch Health in connection with the License,...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three and nine months ended September 30, 2019. Unless otherwise...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the details of its Q3 2019 financial results conference call on Thursday, November 7, 2019. CONFERENCE CALL...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has received Health Canada approval, on October 10, 2019, for TRULANCE® (plecanatide), a Guanylate cyclase-C...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three months ended June 30, 2019. Unless otherwise noted, all figures...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q2 2019 financial results conference call on Friday, August 9, 2019. CONFERENCE CALL DETAILS DATE: